Total | Model 1 | Model 2 | Model 3 | |||||||
---|---|---|---|---|---|---|---|---|---|---|
< 18.5 | 18.5–25 | P value | 18.5–25 | 25–28 | P value | 18.5–25 | ≥28 | P value | ||
No. of patients | 295 | 37 | 37 | 48 | 48 | 12 | 12 | |||
Follow-up time (months) | 45.4 ± 26.6 | 36.3 ± 24.0 | 43.3 ± 23.6 | 0.158 | 41.5 ± 23.1 | 43.9 ± 34.3 | 0.682 | 40.4 ± 28.2 | 41.5 ± 21.6 | 0.810 |
eGFR (ml/min per 1.73 m2) | 88.82 ± 31.57 | 103.84 ± 34.25 | 99.83 ± 34.91 | 0.406 | 83.99 ± 33.18 | 83.75 ± 29.88 | 0.809 | 76.32 ± 41.11 | 87.41 ± 30.83 | 0.722 |
Proteinuria (g/24 h) | 1.60 ± 8.78 | 0.60 ± 0.46 | 0.74 ± 0.69 | 0.567 | 0.84 ± 0.82 | 1.01 ± 0.85 | 0.105 | 1.22 ± 0.99 | 1.39 ± 1.43 | 0.786 |
Treatment | ||||||||||
P | 17 | 2 | 2 | 1 | 4 | 2 | 0.677 | 0 | 0 | 1 |
P + CTX | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 |
P + LEF | 5 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 |
ACEI/ARB | 70 | 10 | 8 | 0.787 | 8 | 14 | 0.224 | 3 | 2 | 1 |
P + ACEI/ARB | 81 | 6 | 12 | 0.173 | 14 | 11 | 0.642 | 4 | 5 | 1 |